Ra-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients . (2019). Journal of Analytical Oncology, 8, 71-76. https://doi.org/10.30683/1927-7229.2019.08.10